KNX-101
| Clinical data | |
|---|---|
| Other names | KNX101 |
| Drug class | ALOX15 inhibitor |
KNX-101 is a 15-lipoxygenase (15-LOX; ALOX15) inhibitor which is under development for the treatment of chronic agitation and aggression as well as acute and chronic pain.[1][2] Whereas its predecessor KNX-100 (SOC-1) is described as a "short-acting" 15-LOX inhibitor, KNX-101 is said to be a "long-acting" 15-LOX inhibitor.[1][2] Both KNX-100 and KNX-101 produce antiaggressive effects without causing sedation in the chronic social isolation model in rodents, whereas the atypical antipsychotic risperidone only reduces aggression at doses that also induce sedation.[1] KNX-101 is under development by Kinoxis Therapeutics.[1][2] As of January 2026, it is in the preclinical research stage of development.[1][2]
See also
- List of investigational agitation drugs
- List of investigational aggression drugs
- List of investigational analgesics
- KNX-100 (SOC-1)
References
- ^ a b c d e Bowen M (11 January 2026). Developing Novel ALOX15 Inhibitors for Dementia and Pain, High-Need CNS Indications. Sachs Associates 9th Annual Neuroscience Innovation Forum for Business Development, Licensing & Investment, 11th January 2026, Marines' Memorial Club, San Francisco, USA.
- ^ a b c d "Pipeline". Kinoxis Therapeutics. Kinoxis Therapeutics. 29 May 2026. Retrieved 1 June 2026.